Emerging treatment options for relapsed and refractory multiple myeloma: A post-ASH discussion Academic Article uri icon


MeSH Major

  • Immunoglobulin Light Chains
  • Multiple Myeloma


  • Multiple myeloma is the second most common hematologic malignancy. Almost all patients who survive initial treatment will eventually relapse and require further therapy. Despite the availability of newer drugs such as bortezomib and lenalidomide, patients with relapsed or refractory multiple myeloma continue to have very limited treatment options and a restricted life expectancy. Several agents that have shown promise in treating relapsed or refractory multiple myeloma patients are currently in phase III clinical trials. Some of these novel agents work through new mechanisms, whereas others represent the next generation of existing medications. Agents with acceptable efficacy and low toxicity are better suited for relapsed patients who receive consecutive therapies. Moreover, agents with new mechanisms may be judiciously combined with existing agents to avoid overlapping toxicities. © 2012 Millennium Medical Publishing, Inc.

publication date

  • April 2012



  • Academic Article

Additional Document Info

start page

  • 1

end page

  • 2


  • 10


  • 4